MedTrace Logo

Pentoxifylline and Progression of Chronic Kidney Disease in Moderate-to-high Risk Patients

NCT00285298 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2011-07-29

No results posted yet for this study

Summary

The purpose of the investigators study is to assess the impact of therapy with Pentoxifylline (PTF), a nonspecific phosphodiesterase inhibitor, on kidney function in patients at high-risk for progression to end-stage renal disease. The investigators hypothesize that therapy with Pentoxifylline will slow progression of kidney disease over time.

Conditions

  • Kidney Failure, Chronic

Interventions

DRUG

Pentoxifylline

DRUG

Placebo

Sponsors & Collaborators

  • National Kidney Foundation, United States

    collaborator OTHER

  • Walter Reed Army Medical Center

    lead FED

Principal Investigators

  • Robert M Perkins, MD · Walter Reed Army Medical Center, Nephrology Service

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-04-30
Completion
2008-04-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00285298 on ClinicalTrials.gov